# AstraZeneca plans $50B US investment including Virginia manufacturing centre

AstraZeneca announced a $50 billion investment in the US by 2030, including a new multi-billion dollar drug substance manufacturing centre in Virginia for weight management and metabolic medicines.

- Type: Investment
- Announced: 2025-07-21
- Where: Commonwealth of Virginia, USA, United States
- Value: $50.0B
- Status: announced
- Products: drug substances for weight management and metabolic portfolio (oral GLP-1, baxdrostat, oral PCSK9, combination small molecules)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [AstraZeneca](https://endata.com/companies/35467.md)

## Sources

- [astrazeneca.com](https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html), 2025-07-21: "AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.